Byondis B.V.
https://www.byondis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Byondis B.V.
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.
Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Synthon Biopharmaceuticals B.V.